Trials / Conditions / Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors

11 registered clinical trials studyying Gastroenteropancreatic Neuroendocrine Tumors — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metast NCT07165886	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	Phase 2 / Phase 3
Active Not Recruiting	Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs NCT04711135	Advanced Accelerator Applications	Phase 2
Completed	Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP- NCT04524442	Advanced Accelerator Applications	Phase 4
Completed	Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors NCT03043664	Duke University	Phase 1 / Phase 2
Completed	[68 Ga]-DOTANOC PET/CT in GEP-NETs NCT02608203	Assistance Publique Hopitaux De Marseille	Phase 2 / Phase 3
Completed	Community-based Neuroendocrine Tumor (NET) Research Study NCT02730104	Ipsen	—
Completed	Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET NCT02231762	Ipsen	Phase 2
Completed	68Ga-OPS202 Study for Diagnostic Imaging of GEP NET NCT02162446	Ipsen	Phase 1 / Phase 2
Completed	Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs NCT02630654	Ipsen	—
Terminated	Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) NCT02078843	Insel Gruppe AG, University Hospital Bern	Phase 1 / Phase 2
Completed	177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs NCT01842165	Jules Bordet Institute	Phase 3